Navigation Links
Signalife Announces AFL Joins NIH Education Program
Date:6/17/2008

LOS ANGELES, June 17 /PRNewswire-FirstCall/ -- Signalife, Inc. (Amex: SGN) and Athletes for Life Foundation announced that the Athletes for Life Foundation will conduct heart monitoring and screening at the Pontotoc Technology Center in Ada, Oklahoma. Willie Gault, Olympic gold medalist, Super Bowl champion, and a founder of the Athletes for Life Foundation, will be present on June 24-25th to participate in a children's health education program sponsored by the National Library of Medicine (NLM), a division of the National Institute of Health's (NIH).

The Athletes for Life Foundation has selected Signalife's award winning technology to perform heart monitoring and screening as part of the program's activities. The Signalife monitor is a 12 lead ambulatory ECG device capable of detecting subtle ECG changes that may be significant for early diagnosis of potential heart problems.

The Athletes for Life Foundation's co-founder, Willie Gault, commented: "I cannot begin to put into words how grateful I am to the NIH for inviting me to join their efforts in educating children. The foundation is bringing Signalife's heart monitoring and screening to the public, for free, as part of its continued effort to shift the healthcare balance from costly reactive heart disease treatments to early heart disease detection. A number of high profile sports and media personalities have recently passed away from heart disease. Perhaps use of this technology would have allowed life saving intervention. The foundation believes that providing annual heart screening for all people, before symptoms are apparent, can have an enormous impact in our efforts to save lives and lower the cost of healthcare throughout the world. We are thankful to all those who have supported our efforts to 'save lives, one heart at a time'."

About Athletes for Life Foundation

The Athletes for Life Foundation, http://www.athletesforlife.com, is a non-profit foundation whose membership includes a multitude of famous role models and athletes who have witnessed friends and colleagues die suddenly from cardiac disease. The Athletes for Life Foundation is committed to promoting early diagnosis and treatment of cardiac disease in order to save lives. The Athletes for Life Foundation is committed to bringing -- and does bring -- new technologies to healthcare. The Athletes for Life Foundation brings heart monitoring to communities, so that health care comes to the masses and not vice versa, in its mission to "save lives, one heart at a time."

Contact:

Athletes for Life Foundation:

Donations or event info:

Steve Cantrell

(562) 858-6717

AthletesforLife.com

About Signalife

Signalife, Inc., http://www.signalife.com, is a life sciences company focused on the monitoring, detection and prevention of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to develop medical devices that provide clear trusted data acquisition to enable accurate timely diagnosis of heart disease. Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.signalife.com.

Contact:

Signalife, Inc.:

Investor relations

Michael Phillips

970-393-3996

info@signalife.com

Caution Regarding Forward-Looking Statement

Statements in this release that are not strictly historical are "forward-looking" statements. Forward-looking statements involve known and unknown risks, which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife's technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife's technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife's technology, and the unavailability of financing to complete management's plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife's technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Signalife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Signalife Appoints Lee Ehrlichman President and Chief Operating Officer
2. Signalife Appoints Lee Ehrlichman as Company Director and Operations Director; Additional Notice Received From Amex Regarding Sharholders Equity Deficiency
3. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
4. Signalife Announces Webcast
5. AMEX Notifies Signalife That It Has Accepted Signalifes Plan of Compliance
6. Signalife Sees Accretive Purchase and Financial Commitments
7. Signalife Wins Second Frost & Sullivan Technology Award
8. Signalife & Athletes Foundation Dispatch Mobile Health Center to Super Bowl
9. AMEX Notifies Signalife that It Will Need to Comply with Minimum Stockholders Equity Requirement
10. Signalife Presence at XIII World Congress on Cardiac Pacing and Electrophysiology
11. U.S. Patent 7,299,083 Awarded to Signalife
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... (PRWEB) , ... December 05, 2016 , ... ... MA to soon resume cervical and lumbar disc production, company President, Jake Lubinski ... surgeons who are implanting the AxioMed disc in Cologne and Karlsruhe to discuss ...
(Date:12/5/2016)... 5, 2016 /PRNewswire/ - Resverlogix Corp. ("Resverlogix" or ... Data and Safety Monitoring Board (DSMB) for the ... disease (CVD) patients has completed a second planned ... continue as planned without any modifications. The DSMB ... safety or efficacy concerns were identified. The DSMB ...
(Date:12/5/2016)... Research and Markets has announced the ... Technologies, Markets and Companies" to their offering. ... , , ... human genome variations, development of sequencing technologies, and their applications. ... companies developing them. Various applications of sequencing are described including ...
(Date:12/4/2016)... San Francisco, CA (PRWEB) , ... December 03, ... ... scientific grants to ground-breaking microbiome studies. A microbiome impact grant award has been ... study the effect of heavy smoking and drinking on the oral microbiome. Grant ...
Breaking Biology Technology:
(Date:12/6/2016)... Dec. 6, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... an offering of €500.0 million principal amount of its 1.414% ... of its 2.425% senior unsecured notes due 2026. ... on December 13, 2016, subject to the satisfaction of customary closing ... The Company intends to use ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
(Date:12/6/2016)... Dec. 6, 2016 Securus Technologies, a ... solutions for public safety, investigation, corrections and monitoring, ... today a five (5) year funding commitment by ... expand the rehabilitation and reentry support to more ... Established in 2004, the Prison Entrepreneurship Program (PEP) ...
Breaking Biology News(10 mins):